Glow LifeTech (FRA:9DO) ROE % Adjusted to Book Value: -2.97% (As of Mar. 2026)


What is Glow LifeTech ROE % Adjusted to Book Value?

Glow LifeTech FRA:9DO +18.18% ROE % Adjusted to Book Value is -2.97% as of Mar. 2026. The stock has 1 warning sign investors should review.

Glow LifeTech's ROE % for the quarter that ended in Mar. 2026 was -8.02%. Glow LifeTech's PB Ratio for the quarter that ended in Mar. 2026 was 2.70. Glow LifeTech's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -2.97%.

Glow LifeTech ROE % Adjusted to Book Value Related Terms

Glow LifeTech ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Glow LifeTech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glow LifeTech ROE % Adjusted to Book Value Chart

Glow LifeTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -146.81 -19.80 0.00 -129.59 -9.01

Glow LifeTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.96 -26.76 -8.03 0.10 -2.97

FRA:9DO vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Glow LifeTech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Glow LifeTech ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glow LifeTech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Glow LifeTech's ROE % Adjusted to Book Value falls into.


Glow LifeTech ROE % Adjusted to Book Value Calculation

Glow LifeTech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-22.52% / 2.50
=-9.01%

Glow LifeTech's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.02% / 2.70
=-2.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -2.97% mean?
Glow LifeTech (FRA:9DO) has a ROE % Adjusted to Book Value of -2.97% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Glow LifeTech and its competitors.
Is Glow LifeTech's ROE % Adjusted to Book Value too high?
Glow LifeTech's current ROE % Adjusted to Book Value is -2.97%.
How does Glow LifeTech's ROE % Adjusted to Book Value compare to VRTX and REGN?
Glow LifeTech's ROE % Adjusted to Book Value of -2.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Glow LifeTech and its competitors. Glow LifeTech's current ROE % Adjusted to Book Value is -2.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glow LifeTech stock overvalued right now?
Glow LifeTech (FRA:9DO) has a current ROE % Adjusted to Book Value of -2.97%. The current ROE % Adjusted to Book Value is -2.97%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Glow LifeTech (FRA:9DO), the current ROE % Adjusted to Book Value is -2.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Glow LifeTech Business Description

Address 65 International Boulevard, Suite 103, Etobicoke, ON, CAN, M9W 6L9
Glow LifeTech Corp is a biotechnology company engaged in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts. Its plant-based MyCell Technology delivery system transforms poorly absorbed natural compounds into enhanced water-compatible concentrates, unlocking the full healing potential of natural active compounds.